These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38176993)

  • 21. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective.
    Ahmed M; Li LC
    Int J Urol; 2013 Apr; 20(4):362-71. PubMed ID: 23163774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
    Melchardt T; Magnes T; Hufnagl C; Thorner AR; Ducar M; Neureiter D; Tränkenschuh W; Klieser E; Gaggl A; Rösch S; Rasp G; Hartmann TN; Pleyer L; Rinnerthaler G; Weiss L; Greil R; Egle A
    Eur J Cancer; 2018 Apr; 93():69-78. PubMed ID: 29477794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic basis and clonal evolution of human prostate cancer.
    Kallioniemi OP; Visakorpi T
    Adv Cancer Res; 1996; 68():225-55. PubMed ID: 8712069
    [No Abstract]   [Full Text] [Related]  

  • 25. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma.
    Bostwick DG; Shan A; Qian J; Darson M; Maihle NJ; Jenkins RB; Cheng L
    Cancer; 1998 Nov; 83(9):1995-2002. PubMed ID: 9806659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis.
    Henrique R; Jerónimo C; Teixeira MR; Hoque MO; Carvalho AL; Pais I; Ribeiro FR; Oliveira J; Lopes C; Sidransky D
    Mol Cancer Res; 2006 Jan; 4(1):1-8. PubMed ID: 16446401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
    Guo Z; Huang H; Zeng L; Du T; Xu K; Lin T; Jiang C; Dong W; Cao Y; Chen J; Zhong W; Huang J
    Med Oncol; 2011 Sep; 28(3):878-87. PubMed ID: 20390466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA ploidy and proliferation heterogeneity in human prostate cancers.
    Shankey TV; Jin JK; Dougherty S; Flanigan RC; Graham S; Pyle JM
    Cytometry; 1995 Sep; 21(1):30-9. PubMed ID: 8529468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells.
    Dago AE; Stepansky A; Carlsson A; Luttgen M; Kendall J; Baslan T; Kolatkar A; Wigler M; Bethel K; Gross ME; Hicks J; Kuhn P
    PLoS One; 2014; 9(8):e101777. PubMed ID: 25084170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic challenges of clonal heterogeneity in prostate cancer.
    Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
    J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
    [No Abstract]   [Full Text] [Related]  

  • 31. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
    Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues.
    Li SS
    Kaohsiung J Med Sci; 1996 Aug; 12(8):441-7. PubMed ID: 8774111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening.
    Ficarra V; Novara G; Zattoni F
    Eur Urol; 2010 Oct; 58(4):482-4; discussion 484-5. PubMed ID: 20685032
    [No Abstract]   [Full Text] [Related]  

  • 35. Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
    Yamamichi G; Kato T; Watabe T; Hatano K; Uemura M; Nonomura N
    Anticancer Res; 2024 Mar; 44(3):879-888. PubMed ID: 38423627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PSMA expression is highly homogenous in primary prostate cancer.
    Tsourlakis MC; Klein F; Kluth M; Quaas A; Graefen M; Haese A; Simon R; Sauter G; Schlomm T; Minner S
    Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):449-55. PubMed ID: 26153794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer: Multilayered mutation analysis indicates divergent clonal evolution.
    Thoma C
    Nat Rev Urol; 2016 Apr; 13(4):179. PubMed ID: 26902334
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
    Luiting HB; van Leeuwen PJ; Remmers S; Donswijk M; Busstra MB; Bakker IL; Brabander T; Stokkel M; van der Poel HG; Roobol MJ
    J Urol; 2020 Sep; 204(3):503-510. PubMed ID: 32149575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advancing a clinically relevant perspective of the clonal nature of cancer.
    Ruiz C; Lenkiewicz E; Evers L; Holley T; Robeson A; Kiefer J; Demeure MJ; Hollingsworth MA; Shen M; Prunkard D; Rabinovitch PS; Zellweger T; Mousses S; Trent JM; Carpten JD; Bubendorf L; Von Hoff D; Barrett MT
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12054-9. PubMed ID: 21730190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous Metastasis of Prostate Adenocarcinoma.
    Vega-González I; López Vélez LM; Cadavid T; Ramírez Fontalvo JC; Ramírez Yepes JC
    Radiol Imaging Cancer; 2023 Jul; 5(4):e230037. PubMed ID: 37449916
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.